Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18005153 | 0.93 | TGFBR1 (1.00) | TGFBR1NTRK1 | |
| SCHEMBL20178956 | 0.90 | TGFBR1 (0.81) | TGFBR1 | |
| SCHEMBL18005146 | 0.88 | TGFBR1 (1.00) | TGFBR1NTRK1 | |
| SCHEMBL20178961 | 0.88 | TGFBR1 (0.77) | TGFBR1NTRK1 | |
| SCHEMBL18005286 | 0.84 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18005228 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18005411 | 0.80 | TGFBR1 (1.00) | TGFBR1NTRK1 | |
| SCHEMBL18005269 | 0.76 | TGFBR1 (1.00) | TGFBR1NTRK1 | |
| SCHEMBL30117522 | 0.74 | TGFBR1 (0.66) | TGFBR1NTRK1 | |
| SCHEMBL15639113 | 0.74 | TGFBR1 (0.66) | TGFBR1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | claimed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | claimed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | claimed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | CXCL8, MSTN, LGALS8 | TGFBR1 249/4885NTRK1 1104/4885TGFBR2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.